Top Markets
#1 Black Phoenix Black Phoenix +736.87%
#2 Beam Beam +34.66%
#3 Tutorial Tutorial +22.08%
#4 SAFEcoin SAFEcoin +19.82%
#5 THORChain THORChain +18.69%
#6 Bless Bless +17.59%
#7 EfficientFrontier EfficientFrontier +14.98%
#8 THORChain Yield THORChain Yield +14.02%
#9 Versatize Coin Versatize Coin +12.50%
#10 TENDIES TENDIES +11.94%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Rank in Stocks #5676
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Share Price
$62.49
Last synced: 2024-03-06
Market Cap
$2.52B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade RayzeBio, Inc. Common Stock (RYZB)

Category

Healthcare
P/E ratio for RayzeBio, Inc. Common Stock (RYZB)
P/E ratio as of 2026 TTM: 0
According to RayzeBio, Inc. Common Stock latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for RayzeBio, Inc. Common Stock from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.